Histone deacetylase inhibition and estrogen signalling in human breast cancer cells
Authors:
- Raphaël MargueronRMRaphaël Margueron
- Vanessa DuongVDVanessa Duong
- Audrey CastetACAudrey Castet
- Vincent CavaillèsVCVincent Cavaillès
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 68 (6) , 1239-1246
Abstract
No abstract availableKeywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Université de Montpellier
This publication has 54 references indexed in Scilit:
- Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogensJournal of Molecular Endocrinology, 2004
- Histone deacetylasesCurrent Opinion in Pharmacology, 2003
- Histone deacetylase inhibitors: from target to clinical trialsExpert Opinion on Investigational Drugs, 2002
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Estrogen receptor and breast cancerSeminars in Cancer Biology, 2001
- Histone deacetylase as a therapeutic targetTrends in Endocrinology & Metabolism, 2001
- Translating the Histone CodeScience, 2001
- Genes modulated by histone acetylation as new effectors of butyrate activityFEBS Letters, 2001
- Transcription therapy for cancerOncogene, 2001
- Endocrine Treatment of Breast Cancer in WomenEndocrine Reviews, 1990